IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9303027 B1

PDFFull Text
Date of Patent:
Apr. 05, 2016

Filed:

Jul. 19, 2011

Kappa opioid receptor agonists

Applicants:

Pradip Kumar Sasmal, Hyderabad, IN;

Vamsee Krishna Chintakunta, Hyderabad, IN;

Vijay Potluri, Hyderabad, IN;

Ish Kumar Khanna, Alpharetta, GA (US);

Ashok Tehim, Ridgewood, NJ (US);

Mahaboobi Jaleel, Hyderabad, IN;

Thomas Hogberg, Akarp, SE;

Oystein Rist, Ballerup, DK;

Lisbeth Elster, Herlev, DK;

Thomas Michael Frimurer, Copenhagen S., DK;

Lars-ole Gerlach, Vedbaek, DK;

Inventors:

Pradip Kumar Sasmal, Hyderabad, IN;

Vamsee Krishna Chintakunta, Hyderabad, IN;

Vijay Potluri, Hyderabad, IN;

Ish Kumar Khanna, Alpharetta, GA (US);

Ashok Tehim, Ridgewood, NJ (US);

Mahaboobi Jaleel, Hyderabad, IN;

Thomas Hogberg, Akarp, SE;

Oystein Rist, Ballerup, DK;

Lisbeth Elster, Herlev, DK;

Thomas Michael Frimurer, Copenhagen S., DK;

Lars-Ole Gerlach, Vedbaek, DK;

Assignees:

DR. REDDY'S LABORATORIES LTD., Hyderabad, IN;

DR. REDDY'S LABORATORIES, INC., Bridgewater, NJ (US);

Attorneys:

Pergament & Cepeda LLP

Milagros A. Cepeda

Edward D. Pergament

Primary Examiner:

James D Anderson

Int. Cl.
CPC ...
C07D 419/12 (2006.01); C07D 207/09 (2006.01); C07D 401/12 (2006.01); C07D 403/12 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 417/12 (2006.01); C07D 207/12 (2006.01); C07D 209/34 (2006.01); C07D 213/76 (2006.01); C07D 215/12 (2006.01); C07D 215/227 (2006.01); C07D 231/56 (2006.01); C07D 249/18 (2006.01); C07D 261/20 (2006.01); C07D 263/56 (2006.01); C07D 263/58 (2006.01); C07D 275/06 (2006.01); C07D 277/30 (2006.01); C07D 279/02 (2006.01); C07D 295/13 (2006.01);
U.S. Cl.
CPC ...
C07D 419/12 (2013.01); C07D 207/09 (2013.01); C07D 207/12 (2013.01); C07D 209/34 (2013.01); C07D 213/76 (2013.01); C07D 215/12 (2013.01); C07D 215/227 (2013.01); C07D 231/56 (2013.01); C07D 249/18 (2013.01); C07D 261/20 (2013.01); C07D 263/56 (2013.01); C07D 263/58 (2013.01); C07D 275/06 (2013.01); C07D 277/30 (2013.01); C07D 279/02 (2013.01); C07D 295/13 (2013.01); C07D 401/12 (2013.01); C07D 403/12 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01);
Abstract

The present invention relates to a series of substituted compounds having the general formula (I), including their stereoisomers and/or their pharmaceutically acceptable salts. (I) Wherein A, m, R1s, R2, R3, R4 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

Find Patent Forward Citations

Loading…